vs
Side-by-side financial comparison of ASTROTECH Corp (ASTC) and Dianthus Therapeutics, Inc. (DNTH). Click either name above to swap in a different company.
Dianthus Therapeutics, Inc. is the larger business by last-quarter revenue ($284.0K vs $148.0K, roughly 1.9× ASTROTECH Corp). ASTROTECH Corp runs the higher net margin — -2653.4% vs -22687.3%, a 20033.9% gap on every dollar of revenue. On growth, ASTROTECH Corp posted the faster year-over-year revenue change (-43.3% vs -78.6%). ASTROTECH Corp produced more free cash flow last quarter ($-4.0M vs $-47.1M). Over the past eight quarters, ASTROTECH Corp's revenue compounded faster (-40.2% CAGR vs -44.6%).
Astrotech Corporation, formerly Spacehab Inc., is a technology incubator headquartered in Austin, Texas. Astrotech uses technology sourced internally and from research institutions, government laboratories, and universities to fund, manage and sell start-up companies. Astrotech Corporation's subsidiaries provide commercial products and services to NASA, the U.S. Department of Defense, national space agencies, and global commercial customers.
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
ASTC vs DNTH — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.0K | $284.0K |
| Net Profit | $-3.9M | $-64.4M |
| Gross Margin | 5.4% | — |
| Operating Margin | -2635.8% | -24486.3% |
| Net Margin | -2653.4% | -22687.3% |
| Revenue YoY | -43.3% | -78.6% |
| Net Profit YoY | 2.0% | -126.6% |
| EPS (diluted) | — | $-1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.0K | $284.0K | ||
| Q3 25 | $297.0K | $396.0K | ||
| Q2 25 | $220.0K | — | ||
| Q1 25 | $534.0K | $1.2M | ||
| Q4 24 | $261.0K | $1.3M | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $874.0K |
| Q4 25 | $-3.9M | $-64.4M | ||
| Q3 25 | $-3.5M | $-36.8M | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-3.6M | $-29.5M | ||
| Q4 24 | $-4.0M | $-28.4M | ||
| Q3 24 | — | $-25.2M | ||
| Q2 24 | — | $-17.6M | ||
| Q1 24 | — | $-13.7M |
| Q4 25 | 5.4% | — | ||
| Q3 25 | 63.3% | — | ||
| Q2 25 | 33.6% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 59.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -2635.8% | -24486.3% | ||
| Q3 25 | -1190.6% | -10173.7% | ||
| Q2 25 | -1326.4% | — | ||
| Q1 25 | -724.2% | -2852.7% | ||
| Q4 24 | -1655.6% | -2406.9% | ||
| Q3 24 | — | -1376.6% | ||
| Q2 24 | — | -1191.8% | ||
| Q1 24 | — | -2041.6% |
| Q4 25 | -2653.4% | -22687.3% | ||
| Q3 25 | -1166.7% | -9284.1% | ||
| Q2 25 | -1331.8% | — | ||
| Q1 25 | -680.3% | -2537.5% | ||
| Q4 24 | -1536.0% | -2144.8% | ||
| Q3 24 | — | -1159.0% | ||
| Q2 24 | — | -945.1% | ||
| Q1 24 | — | -1573.0% |
| Q4 25 | — | $-1.53 | ||
| Q3 25 | — | $-0.97 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.82 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.74 | ||
| Q2 24 | — | $-0.51 | ||
| Q1 24 | — | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $404.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.5M | $493.4M |
| Total Assets | $19.7M | $530.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | $404.3M | ||
| Q3 25 | $11.3M | $402.6M | ||
| Q2 25 | $15.1M | — | ||
| Q1 25 | $18.1M | $263.2M | ||
| Q4 24 | $21.5M | $275.2M | ||
| Q3 24 | — | $281.1M | ||
| Q2 24 | — | $360.7M | ||
| Q1 24 | — | $377.0M |
| Q4 25 | $15.5M | $493.4M | ||
| Q3 25 | $19.1M | $546.5M | ||
| Q2 25 | $22.1M | — | ||
| Q1 25 | $24.8M | $328.6M | ||
| Q4 24 | $28.1M | $352.5M | ||
| Q3 24 | — | $337.9M | ||
| Q2 24 | — | $358.2M | ||
| Q1 24 | — | $372.7M |
| Q4 25 | $19.7M | $530.9M | ||
| Q3 25 | $23.2M | $577.4M | ||
| Q2 25 | $27.0M | — | ||
| Q1 25 | $27.5M | $348.6M | ||
| Q4 24 | $31.0M | $374.0M | ||
| Q3 24 | — | $354.2M | ||
| Q2 24 | — | $369.0M | ||
| Q1 24 | — | $382.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | $-47.0M |
| Free Cash FlowOCF − Capex | $-4.0M | $-47.1M |
| FCF MarginFCF / Revenue | -2671.6% | -16591.9% |
| Capex IntensityCapex / Revenue | 277.7% | 48.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-14.9M | $-132.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.5M | $-47.0M | ||
| Q3 25 | $-3.9M | $-30.6M | ||
| Q2 25 | $-2.4M | — | ||
| Q1 25 | $-3.9M | $-27.6M | ||
| Q4 24 | $-3.0M | $-27.4M | ||
| Q3 24 | — | $-21.3M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-14.9M |
| Q4 25 | $-4.0M | $-47.1M | ||
| Q3 25 | $-4.4M | $-30.6M | ||
| Q2 25 | $-2.7M | — | ||
| Q1 25 | $-3.9M | $-27.7M | ||
| Q4 24 | $-3.4M | $-27.5M | ||
| Q3 24 | — | $-21.3M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-15.0M |
| Q4 25 | -2671.6% | -16591.9% | ||
| Q3 25 | -1476.1% | -7717.2% | ||
| Q2 25 | -1231.4% | — | ||
| Q1 25 | -728.1% | -2377.8% | ||
| Q4 24 | -1288.5% | -2072.0% | ||
| Q3 24 | — | -980.3% | ||
| Q2 24 | — | -780.7% | ||
| Q1 24 | — | -1713.2% |
| Q4 25 | 277.7% | 48.6% | ||
| Q3 25 | 150.8% | 1.3% | ||
| Q2 25 | 158.2% | — | ||
| Q1 25 | 5.1% | 2.1% | ||
| Q4 24 | 122.2% | 2.3% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 3.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
